These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26481056)

  • 1. A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA).
    Jagdeo J; Ho D; Lo A; Carruthers A
    J Am Acad Dermatol; 2015 Dec; 73(6):1040-54.e14. PubMed ID: 26481056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of a Volumizing Hyaluronic Acid Filler for Treatment of HIV-Associated Facial Lipoatrophy.
    Ho D; Jagdeo J
    JAMA Dermatol; 2017 Jan; 153(1):61-65. PubMed ID: 27806168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Reported Outcomes from HIV Facial Lipoatrophy Treatment With a Volumizing Hyaluronic Acid Filler: A Prospective, Open-Label, Phase I and II Study.
    Ho D; Jagdeo J
    J Drugs Dermatol; 2016 Sep; 15(9):1064-9. PubMed ID: 27602967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semipermanent filler treatment of HIV-positive patients with facial lipoatrophy: long-term follow-up evaluating MR imaging and quality of life.
    van Rozelaar L; Kadouch JA; Duyndam DA; Nieuwkerk PT; Lutgendorff F; Karim RB
    Aesthet Surg J; 2014 Jan; 34(1):118-32. PubMed ID: 24334306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
    Burgess CM; Quiroga RM
    J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review.
    Kates LC; Fitzgerald R
    Aesthet Surg J; 2008; 28(4):397-403. PubMed ID: 19083552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes.
    Shuck J; Iorio ML; Hung R; Davison SP
    Plast Reconstr Surg; 2013 Mar; 131(3):499-506. PubMed ID: 23142937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs.
    Treacy PJ; Goldberg DJ
    Dermatol Surg; 2006 Jun; 32(6):804-8. PubMed ID: 16792645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life outcomes associated with treatment of human immunodeficiency virus (HIV) facial lipoatrophy.
    Kraus CN; Chapman LW; Korta DZ; Zachary CB
    Int J Dermatol; 2016 Dec; 55(12):1311-1320. PubMed ID: 27496689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
    Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
    Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly-L-lactic acid: a new dimension in soft tissue augmentation.
    Rotunda AM; Narins RS
    Dermatol Ther; 2006; 19(3):151-8. PubMed ID: 16784514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV facial lipoatrophy: causes and treatment options.
    Jones D
    Dermatol Surg; 2005 Nov; 31(11 Pt 2):1519-29; discussion 1529. PubMed ID: 16416634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.
    Moyle GJ; Brown S; Lysakova L; Barton SE
    HIV Med; 2006 Apr; 7(3):181-5. PubMed ID: 16494632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus.
    Reytan N; Rzany B
    J Drugs Dermatol; 2008 Dec; 7(12):1169-71. PubMed ID: 19137772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment.
    Reytan N; Rzany B
    J Drugs Dermatol; 2008 Sep; 7(9):884-6. PubMed ID: 19112805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of injectable poly-L-lactic acid from the correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies.
    Burgess C
    J Drugs Dermatol; 2011 Sep; 10(9):1001-6. PubMed ID: 22052268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE].
    Lafaurie M; Dolivo M; Girard PM; May T; Bouchaud O; Carbonnel E; Madelaine I; Loze B; Porcher R; Molina JM;
    HIV Med; 2013 Aug; 14(7):410-20. PubMed ID: 23432777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy].
    Thiéry G; Coulet O; Adam S; Guyot L
    Rev Stomatol Chir Maxillofac; 2008 Apr; 109(2):103-5. PubMed ID: 18374957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging.
    Hanke CW; Redbord KP
    J Drugs Dermatol; 2007 Feb; 6(2):123-8. PubMed ID: 17373169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The "smile-and-fill" injection technique: a dynamic approach to midface volumization.
    Wang AS; Babalola O; Jagdeo J
    J Drugs Dermatol; 2014 Mar; 13(3):288-90. PubMed ID: 24595573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.